Precision Medicine Day One


Precision 2018 Day 1

08:00 Registration opens


Welcome from Terrapinn

Opening Keynotes: Implementing precision medicine into clinical practice

Sue Hill

Delivering a national genomic medicine service for personalised care

  • The establishment of the infrastructure and proof of concept for the delivery of genomics through routine care through the 100,000 Genomes Project
  • Demonstrating the value case for genomics through improved diagnostic yield for cancer & rare disease
  • The importance of education, training and wholesale clinical engagement for the mainstreaming of genomics at a countrywide level
  • The future vision for further personalisation of care across clinical specialities
Joanne Hackett

Individualised medicine, and using the genome and digital technologies to understand disease and prevention

  • The value of genomics in healthcare
  • How Genomics England is catalysing the UK genomics landscape
  • How genomic data can diagnose and treat disease
  • Opportunities unique to the UK and why the time is now for harnessing the ecosystem
Panel discussion

Keynote panel: How is precision medicine shaping healthcare and medicine?

  • Diagnostics – defining tumours
  • Liquid biopsies - mapping cancers
  • Targeted drugs
  • Data mining
Joachim Reischl, VP, Head Precision Medicine Policy, Portfolio and Externalisation, AstraZeneca

10:40 Networking Break


Big Data and Genomics

Infrastructure and Investment


Whole genome sequencing as a powerful clinical tool to treat cancers with an HPV etiology

  • Different types of whole genome sequencing- Illumina versus BGI
  • Importance of HPV integration to the eventual cancers that develop
  • Important clinical information gained from whole genome sequencing
  • How WGS information can drive the liquid biopsy
Big Data and Genomics

Creating a digital health strategy; An informatics journey

  • Semantics and Metadata
  • Data catalogs and federated data/analytics
  • Data Governance
  • Using the principles of FAIR data
Dominic Sinibaldi, Senior Scientific Manager, Research Bioinformatics, MedImmune Inc
Infrastructure and Investment

Advancing innovation in personalised medicine through public private partnerships: The innovative medicines Initiative

  • Technology in the post human genome world is driving new disease taxonomies of disease and therefore new pathways for intervention
  • For some complex diseases like Alzheimer’s Disease, Type 2 Diabetes or Cancer, early stage developments can be achieved with lower risk and lower costs through PPPs
  • Patient engagement at early stages of R&D is critical for overall success
  • Bringing all stakeholders to the table including health economists, regulators, payers as well as Academics, Clinicians, SMEs, Patients and industry players is crucial for dealing with complex disease

Some recent advances in host biomarker approach to precision medicine

  • Precision medicine can benefit from validated host biomarkers
  • Validation of host protein and nucleic acid biomarkers for key public health priorities
  • Probable risk, prognosis, diagnosis, treatment response are key considerations for patient stratification
  • Recent examples of advances in biomarker discovery, validation, translational and commercial development
Big Data and Genomics

Oncology – whole genome sequencing

  • IT challenges
  • Big data approaches
  • Molecular tumour board
  • Whole genome sequencing
Infrastructure and Investment

Funding the future through impact investing

While many investors are primarily concerned with returns on investment, many investors and organizations are more dedicated to social returns through the application of capital. In this interactive session, we will discuss various funding sources such as:
  • Traditional venture capital
  • Family Offices and High Net Worth Individuals
  • Government sponsored programs
  • Foundations and Nonprofits

Cloud and security services to manage your big data

Reserved for supporting partner
Please contact Erica Baeta (+44 (0)207 092 1152, or Derek Cavanagh (+44 (0)207 092 1297, for further details

cMyC - how a novel biomarker could transform chest pain triage

  • Cardiac Myosin-binding Protein C (cMyC) is a novel biomarker of myocardial injury.  Over the past 20 years, cardiac Troponin has transformed emergency care around the world
  • Our research demonstrates that cMyC is more abundant than the Troponins and at least as good as the leading Troponin assays in directing immediate triage of patients presenting with suspected acute non-ST elevation myocardial infarction.
  • This property, combined with the analytic sensitivity of our assay, suggests we can detect myocardial injury on a point-of-care platform; thus, improving cardiovascular care for millions of people
Infrastructure and Investment

Investment and PM in Asia


Advantages of large scale sequencing beyond conventional methods

  • Overview of methods for the integrated interpretation of somatic and germline data obtained from large-scale sequencing
  • Results obtained from these methods will be discussed
  • Advantages of large-scale data interpretation compared to conventional methods in cancer will be elucidated
Arezou Ghazani, Instructor in Medicine, Harvard Medical School
Big Data and Genomics

Enablers for scaling up access to big health data

  • The challenges with accessing and combining health data sets at scale
  • Establishing trustworthy governance and privacy protection solutions
  • Data discovery and best practices in data sharing
  • Promoting the adoption of interoperability standards and data quality improvement
  • Demonstrating value to society from reusing their health data for research

13:00 Networking Lunch


Chemical sensing microchip technology for liquid biopsies in breast cancer

  • Latest advances in chemical sensing microchip technology currently being used for genomics and point-of-care diagnostics
  • Recent and exciting results of our research towards the development of a sample-to-result, scalable, Lab-on-Chip system for early detection of breast cancer recurrence
Big Data and Genomics

Will computers be the better doctors soon? Real-world insights from oncology

  • How oncologists already benefit from interdisciplinary cooperation beyond doctors
  • When time matters: flexible real-time data analysis of big medical data at your fingertips using the platform
  • Application examples:
  • Accessing latest international medical expertise through the medical knowledge cockpit to enable personalized therapy decisions
  • Introducing next-generation sequencing to the clinical routine through reproducible high-throughput data processing
  • Individual assessment of available drugs through interactive drug response analysis
  • Enabling patients to manage their personal health data in a holistic way and support medical research at the same time through the data donation pass
Infrastructure and Investment

Accelerating precision health for all of us: the all of us research program

  • Provide an overview of the NIH All of Us Research Program
  • Describe the Infrastructure for digitally driven research resource, from participant engagement to data access
  • Describe data collection plans for enabling precision medicine research

Circulating DNA: a liquid biopsy powerful diagnostic tool

  • The first clinical validation of the analysis of circulating DNA in oncology, in a prospective blinded multicentric study for the detection of KRAS and BRAF mutations from colorectal patient plasma samples
  • Aims of our research are now focusing on various aspects of the potential of ctDNA: (i), detecting the emergence of the mutations following targeted therapy; (ii), developing the Intplex test for the multimarker quantitative analysis of ctDNA; (iii), studying the follow up of CRC patients; (iv), the prognostic power of ctDNA and (v) the screening power of ctDNA
Big Data and Genomics

Large-scale genomics for therapeutics and prevention of cancer

  • Lessons from the Genomics England 100,000 Genomes Project
  • Pan genomic analyses move molecular testing upstream from the metastatic setting to primary diagnosis
  • High penetrance cancer susceptibility genes, common variants and non-genetic factors: integrated data analysis for risk profiling with which to target our resources for screening, prevention and early detection
Infrastructure and Investment

Panel: Funding precision medicine – how to fund your projects

  • What are investors most likely to find compelling in an elevator pitch?
  • Is it the science or the team that attracts capital?
  • How can I obtain access to funding sources?
  • What are the benefits and drawbacks of each capital source?

Using lab developed tests for companion diagnostic development

Reserved for supporting partner
Please contact Erica Baeta (+44 (0)207 092 1152, or Derek Cavanagh (+44 (0)207 092 1297, for further details
Big Data and Genomics

Integrating clinical and genomic information

  • SMART/FHIR Genomics
  • Stakeholders and users
  • Apps, services, and servers
  • Pilots, implementations, and conformance testing

Collaborations across precision medicine

Big Data and Genomics

User Experience for Life Science (UXLS): current trends in life science software development that can enhance research into - and the practice of - precision medicine

Reserved for supporting partner
Please contact Erica Baeta (+44 (0)207 092 1152, or Derek Cavanagh (+44 (0)207 092 1297, for further details

15:50 Networking break

Big Data and Genomics

Advancing drug discovery and gaining a competitive advantage through user experience (UX)

  • Hear about the internal UX design capabilities of nine global research-based biopharmaceutical companies from a new investigation carried out in 2017
  • Find out how your organisation can benefit from a free UX toolkit for life science R&D designed by the Pistoia Alliance “User Experience for Life Sciences” (UXLS) initiative, a feat which involved over 50 UX design experts from 20 life science and tech organisations
  • Discover how UX offers a clear path to differentiating your business and reaping benefits for the discovery pipeline through specific case studies of UX in R&D
Big Data and Genomics

Moving medicine from symptom based to algorithm based diagnosticsHow combining AI and genomics can advance treatment and diagnostics

  • How advances in AI and genomics are shaping medicine
  • The advantages of semantic integration of longitudinal omics data for improving diagnosis prediction
  • How AI-driven solutions can predict response to cancer treatment based on metagenomics information
  • How using AI methods improves traditional variant calling and mutation identification
Collaborations Across Precision Medicine

Getting the most from academic – industrial collaborations in the big data / AI space

  • Scoping the collaboration and contractual synergy – getting it right before you start
  • Key stakeholder alignment and investment – joint teams with a common vision
  • Investment in the future – short term goals are always good but ensuring a longer-term strategy provides confidence to generate the science and ensure the integrity of investigative outcomes
  • Track record of accountability – evidence generation
Big Data and Genomics

Improving the cyber security of your data system

Reserved for supporting partner
Please contact Erica Baeta (+44 (0)207 092 1152, or Derek Cavanagh (+44 (0)207 092 1297, for further details
Collaborations Across Precision Medicine

Collaboration at scale: Pan-regional precision medicines across the North of England's 15m population

  • The Northern Health Science Alliance
  • An overview of the North of England’s health research environment
  • Precision medicine industry engagement at scale
  • Pioneering precision medicine initiatives ready for scale up
Big Data and Genomics

Data in research and drug discovery

  • The American Heart Association has established an Institute for Precision Cardiovascular Medicine
  • The Institute is transforming how we interface with data through four innovative programs, One Brave Idea, the Precision Medicine Platform, My Research Legacy, and the Center for Accelerated Drug Discovery
Jennifer Hall, Chief, Institute for Precision Cardiovascular Medicine, American Heart Association
Collaborations Across Precision Medicine

Collaboration in MedTech translation: academia, industry and the regulator

  • CÚRAM is an Irish national medical device research centre with industry partners 
  • CRDI is partnering with CÚRAM in developing resources to navigate the regulatory environment 
  • This is well-aligned with the work of colleagues in developing methods of clinical and economic evaluation 

18:00 End of Day 1 - Networking drinks reception

last published: 16/Mar/18 13:45 GMT




Sign Up for Event Updates

World Precision Medicine Congress


Erica Baeta
+44 (0)207 092 1152


Joan Shutt
t/ +44 (0)207 092 1134


Issa Mauthoor
+44 (0)207 092 1257